Trials / Completed
CompletedNCT00129818
A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Famciclovir |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2005-10-01
- Completion
- 2005-10-01
- First posted
- 2005-08-12
- Last updated
- 2012-04-27
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00129818. Inclusion in this directory is not an endorsement.